Roche gets Chinese approval for Tecentriq plus chemotherapy to treat ES-SCLC

Roche gets Chinese approval for Tecentriq plus chemotherapy to treat ES-SCLC

Source: 
Pharmaceutical Business Review
snippet: 

Roche has secured approval from the China National Medical Products Administration (NMPA) for Tecentriq (atezolizumab) in combination with chemotherapy (carboplatin and etoposide) as a first-line treatment for patients with extensive-stage small cell lung cancer (ES-SCLC).